REGENXBIO Advances Duchenne Gene Therapy with Positive Trial Data and $200M Capital Boost
Event summary
- RGX-202 Phase III AFFINITY DUCHENNE trial met primary endpoint with high statistical significance (p<0.0001).
- REGENXBIO secured over $200 million in July 2026, including a $100 million milestone payment from AbbVie and $108 million from a public offering.
- Topline data from pivotal subretinal wet AMD studies (ATMOSPHERE® and ASCENT®) expected in Q4 2026.
- FDA reaffirmed the path forward for RGX-121 (NAVSUNLI™) for Hunter syndrome, with BLA resubmission on track for Q3 2026.
The big picture
REGENXBIO's progress in gene therapy for Duchenne muscular dystrophy and retinal diseases positions it as a key player in the curative potential of AAV gene therapies. The $200 million capital raise extends its runway into Q4 2027, providing financial flexibility to advance multiple high-value catalysts. The company's strategic partnerships with AbbVie and Nippon Shinyaku further bolster its pipeline and regulatory pathways.
What we're watching
- Regulatory Timing
- Whether RGX-202 BLA submission in Q3 2026 will lead to accelerated approval in 2H 2027.
- Clinical Data Impact
- How topline data from ATMOSPHERE® and ASCENT® trials in Q4 2026 will influence wet AMD treatment landscape.
- Financial Flexibility
- The pace at which REGENXBIO can extend its cash runway beyond Q4 2027 through additional funding or milestone payments.
Related topics